Nina Maw Maw, MD
Family Medicine · Rancho Mirage, CANPI 1407851777
Payments from drug & device makers
Across 125 payments — averaging $21.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$320
- Abbott$236
- AstraZeneca$232
- AbbVie$199
- Novartis$182
- Lilly USA, LLC$157
- plus $1K from 27 others
What the payments were for
- Food & beverage$2,63396%
- Education$994%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 8 | $320 |
| Abbott | 9 | $236 |
| AstraZeneca | 10 | $232 |
| AbbVie(2 entities) | 11 | $199 |
| Novartis | 9 | $182 |
| Lilly USA, LLC | 7 | $157 |
| GSK | 7 | $152 |
| Novo Nordisk | 8 | $150 |
| Amgen | 9 | $147 |
| Johnson & Johnson | 5 | $95 |
| Pfizer | 4 | $85 |
| Merck | 5 | $84 |
| Astellas Pharma US Inc | 1 | $80 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $79 |
| E.r. Squibb & Sons, L.L.C. | 3 | $76 |
| Amarin Pharma, Inc. | 2 | $44 |
| Mylan Specialty L.p. | 3 | $42 |
| Shield Therapeutics Inc | 1 | $37 |
| Kowa Pharmaceuticals America, Inc. | 2 | $36 |
| Sumitomo Pharma America, Inc. | 2 | $34 |
| Almatica Pharma LLC | 2 | $32 |
| Baxter Healthcare | 1 | $25 |
| Lucid Diagnostics Inc. | 1 | $24 |
| Lundbeck LLC | 1 | $24 |
| Otsuka America Pharmaceutical, Inc. | 1 | $24 |
| Idorsia Pharmaceuticals US Inc | 1 | $21 |
| Hologic Sales And Service, LLC | 1 | $20 |
| Collegium Pharmaceutical, Inc. | 1 | $18 |
| Currax Pharmaceuticals LLC | 1 | $17 |
| Boehringer Ingelheim | 1 | $16 |
| Nevro Corp. | 1 | $15 |
| Arbor Pharmaceuticals, Inc. | 1 | $15 |
| Biohaven Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerendia$240
How this compares
$2,732 in reported general payments places this provider in the 85th percentile of 10,533 family medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 418 | $446,465 |
| OzempicSemaglutide | 205 | $235,980 |
| EliquisApixaban | 179 | $174,462 |
| JardianceEmpagliflozin | 101 | $132,829 |
| JanuviaSitagliptin Phosphate | 62 | $78,626 |
| XareltoRivaroxaban | 56 | $59,744 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 68 | $53,740 |
| MyrbetriqMirabegron | 32 | $32,590 |
| GemtesaVibegron | 33 | $30,209 |
| TrulicityDulaglutide | 22 | $26,760 |
| LinzessLinaclotide | 19 | $22,439 |
| EntrestoSacubitril/Valsartan | 29 | $19,467 |
| FarxigaDapagliflozin Propanediol | 21 | $17,997 |
| PremarinEstrogens, Conjugated | 25 | $14,553 |
| Breo ElliptaFluticasone/Vilanterol | 22 | $13,060 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $157 | $473,225440 claims |
| Novo NordiskOzempic | $150 | $235,980205 claims |
| PfizerEliquis, Premarin, Prempro, Paxlovid | $85 | $205,895288 claims |
| Boehringer IngelheimJardiance | $16 | $132,829101 claims |
| MerckJanuvia | $84 | $78,62662 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $152 | $66,80090 claims |
| Johnson & JohnsonXarelto | $95 | $59,74456 claims |
| Astellas Pharma US IncMyrbetriq | $80 | $32,59032 claims |
| AbbVieLinzess, Synthroid | $199 | $30,547137 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $34 | $30,20933 claims |
| NovartisEntresto | $182 | $19,46729 claims |
| AstraZenecaFarxiga | $232 | $17,99721 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,533 family medicine providers in California.
Other family medicine in Rancho Mirage
- Amina HaggagNorthridge$112.8M
- Steven ReynoldsLong Beach$53M
- Rizwana MohseniLake Forest$26.7M
- Daniel JohnsonSan Diego$15.7M
- Stacey LayleSan Diego$14.8M
- Apinya VutikullirdCypress$14.3M
- Hanid AudishSpring Valley$13.6M
- Augusto FocilOxnard$12.6M
- Jack VuLong Beach$10.1M
- Suzanne FussellOxnard$8.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.